Genome Publications
https://doi.org/10.61096/ 978-81-981372-2-7_1

Chapter 1

Foundations of System-Based Pharmacology and Precision Therapeutics

Santhosh Illendula
Associate Professor, Department of Pharmaceutical Analysis,
Vijaya College of Pharmacy, Munaganoor, Hyderabad, Telangana, India.

Thirumurugan R
Principal, Niveditha College of Pharmacy, Chintamani, Chickballapur District,
Karnataka, India.

Abstract: The chapter explores the foundational transition in pharmacology from organ-specific to system-based and precision-focused approaches, marking a paradigm shift in how drugs are discovered, evaluated, and administered. It begins by reviewing core pharmacokinetic and pharmacodynamic principles, along with receptor theory and signal transduction pathways, which remain the bedrock of therapeutic intervention. Building on this, the chapter delves into systems biology, highlighting how interconnected biological networks influence drug responses and how perturbation of these networks can lead to both therapeutic effects and unintended consequences. Omics technologies genomics, transcriptomics, proteomics, metabolomics, and epigenomics are discussed for their role in uncovering inter-individual variability and guiding targeted therapy. Emphasis is placed on modeling and simulation tools such as PBPK and PopPK models, which integrate patient-specific data to inform evidence-based dosing decisions. The chapter also addresses challenges in systemic integration, including biological complexity, data heterogeneity, and regulatory uncertainties. It further evaluates the evolving regulatory landscape, with companion diagnostics, real-world evidence, and AI-enabled tools playing increasing roles in drug approval and clinical implementation. Finally, future directions are examined, such as AI-driven discovery, digital twin technology, microbiome-informed pharmacology, and the rise of cell- and RNA-based therapies. Together, these developments position system-based pharmacology and precision therapeutics as critical components of 21st-century healthcare, ensuring treatments are both individualized and integrative.

Keywords: System-based pharmacology, Precision therapeutics, Pharmacogenomics, Omics technologies, Model-informed dosing.

Citation: Santhosh Illendula, R. Thirumurugan. Foundations of System-Based Pharmacology and Precision Therapeutics. *Modern Therapeutic Pharmacology: Precision Therapeutics Across Organ Systems*. 2025; Pp1-10. https://doi.org/10.61096/978-81-981372-2-7_1

1.0 INTRODUCTION

The landscape of pharmacology has undergone a significant transformation over the past few decades, moving beyond the traditional organ-specific approach toward an integrated system-based framework. This evolution has been necessitated by the growing complexity of disease biology and the limitations of “one-size-fits-all” therapeutics. The emergence of systems biology and precision medicine has further propelled pharmacology into a new era, where drug development and clinical application are guided by the dynamic interplay between biological networks and individual variability.

System-based pharmacology offers a multidimensional view of drug action, recognizing that pharmacologic effects are rarely confined to a single organ. Instead, drugs influence and are influenced by interconnected signaling pathways, compensatory mechanisms, and host-specific genomic and proteomic profiles. This complexity underscores the importance of integrating pharmacokinetics (PK), pharmacodynamics (PD), and systems-level feedback to optimize therapeutic outcomes and minimize adverse effects.

Precision therapeutics builds on this foundation by tailoring drug regimens based on individual characteristics, including genetic makeup, environmental exposures, microbiome composition, and disease subtypes. It bridges clinical pharmacology with emerging fields such as pharmacogenomics, artificial intelligence, and digital health technologies. As personalized approaches become the norm in clinical decision-making, pharmacologists must adopt holistic, system-aware models to guide drug discovery, evaluation, and application.

This chapter provides an in-depth exploration of the principles underlying system-based pharmacology and precision therapeutics. It begins by revisiting PK/PD concepts and receptor theory, then expands into systems biology, omics-driven drug targeting, and computational modeling. It also examines regulatory frameworks and the future convergence of AI, wearable technologies, and individualized dosing algorithms.

1.1 Basic Principles of Pharmacokinetics and Pharmacodynamics

Pharmacokinetics (PK) describes how the body absorbs, distributes, metabolizes, and eliminates a drug, while pharmacodynamics (PD) focuses on the biological effects and mechanisms of drug action. Together, they determine the drug's concentration-time profile and its therapeutic or toxic impact. Understanding this PK/PD interface is essential for dose optimization, especially in system-based and precision approaches where variability in drug response is anticipated.

The four primary PK processes absorption, distribution, metabolism, and excretion (ADME) are governed by both drug properties and patient-specific factors. For instance, lipophilicity influences membrane permeability, while genetic polymorphisms in cytochrome P450 enzymes (e.g., CYP2D6, CYP3A4) impact metabolism rates [1]. PK modeling helps estimate key parameters such as clearance, volume of distribution, and half-life, all of which are critical in designing dosing regimens that achieve and maintain therapeutic drug levels.

Pharmacodynamics explores the interaction between the drug and its biological target. It includes receptor binding, signal transduction, and downstream physiological responses. Key PD concepts include the Emax model, where a drug’s maximum effect (Emax) and potency (EC50) are defined, and sigmoidal dose-response curves, which illustrate graded effects. These models form the basis for predicting therapeutic windows and toxic thresholds.

A major challenge in traditional pharmacology has been the assumption of linearity and uniformity across patient populations. In contrast, system-based pharmacology acknowledges that both PK and PD are subject to modulation by disease states (e.g., liver dysfunction altering drug metabolism), comorbidities, and even circadian rhythms. Furthermore, feedback mechanisms and compensatory responses often alter drug efficacy over time, necessitating dynamic models that reflect these real-world complexities [2].

Precision dosing aims to overcome inter-individual variability by incorporating patient-specific datasuch as age, renal function, genotype, and body composition into dosing algorithms. Advances in population PK modeling, Bayesian forecasting, and physiologically based pharmacokinetic (PBPK) simulations have enhanced this capability, supporting safer and more effective pharmacotherapy across diverse populations [3].

1.2 Receptor Theory and Signal Transduction Pathways

Receptors are the fundamental molecular targets through which drugs exert their pharmacologic effects. Receptor theory provides a framework for understanding how drugs initiate, amplify, or block biological responses. The interaction between a drug (ligand) and its receptor is characterized by affinity, efficacy, selectivity, and intrinsic activity factors that shape both therapeutic potential and adverse effect profiles.

The earliest formalization of receptor theory was the occupancy theory, which postulates that the intensity of a drug's effect is proportional to the number of receptors occupied. However, this model was later refined by the two-state receptor model and ternary complex model, which better accommodate concepts such as partial agonism and inverse agonism [4]. Agonists stabilize receptors in their active conformations, antagonists prevent activation, and inverse agonists stabilize inactive states.

Receptors are broadly classified based on their structure and signaling mechanisms:

- **G protein-coupled receptors (GPCRs):** Mediate responses to neurotransmitters, hormones, and chemokines; key in cardiovascular and CNS pharmacology.
- **Receptor tyrosine kinases (RTKs):** Involved in growth factor signaling; targeted in oncology (e.g., EGFR inhibitors).
- **Ligand-gated ion channels:** Important in neuropharmacology (e.g., GABA, NMDA receptors).
- **Nuclear receptors:** Regulate gene transcription in response to lipophilic hormones (e.g., corticosteroids, thyroid hormone).

Once activated, receptors initiate signal transduction pathways that translate extracellular signals into cellular responses. These include second messengers like cyclic AMP (cAMP), inositol triphosphate (IP3), and diacylglycerol (DAG), which in turn activate protein kinases, ion channels, and transcription factors [5]. Dysregulation of these pathways is implicated in numerous diseases, making them attractive targets for pharmacologic intervention.

An important concept in receptor pharmacology is desensitization and downregulation, where prolonged exposure to agonists reduces receptor responsiveness. This is common with β-adrenergic agonists and opioid drugs, leading to tolerance and necessitating dose escalation or drug rotation [6].

In system-based pharmacology, receptor theory is integrated with signaling network models to predict system-wide effects. This network perspective acknowledges that a single receptor may participate in multiple pathways and cross-talk with other signaling modules. For example, GPCRs can transactivate RTKs, resulting in complex signaling outcomes that are highly context-dependent.

Modern drug discovery increasingly relies on biased agonism, where ligands are designed to selectively activate beneficial signaling arms (e.g., G-protein vs β-arrest in pathways in opioid receptors), reducing adverse effects while preserving efficacy [7]. Such approaches require detailed mapping of receptor conformations and downstream signalling cascades advances made possible through structural biology, cryo-EM, and systems modelling.

1.3 Systems Biology in Drug Response

Systems biology represents a paradigm shift in biomedical research and pharmacology. Instead of studying isolated pathways or targets, it views biological processes as interconnected networks of genes, proteins, metabolites, and signaling pathways that operate dynamically across time and space. This holistic framework is especially relevant for pharmacology, where drug actions ripple across multiple levels of biological organization from molecular interactions to cellular behavior and organ-level physiology.

In pharmacological systems biology, drugs are not seen merely as receptor ligands but as perturbagens that disrupt or modulate complex biochemical networks. These perturbations can produce both desired therapeutic effects and unintended consequences, depending on how the system adapts or compensates. For instance, statins reduce cholesterol by inhibiting HMG-CoA reductase, but they also activate feedback loops that upregulate LDL receptor expression enhancing lipid clearance [8].

Key components of systems biology in pharmacology include:

- **Network pharmacology**: Mapping drug-target interactions onto molecular networks to identify synergistic or off-target effects.
- **Omics integration**: Combining transcriptomics, proteomics, and metabolomics data to understand system-wide drug responses.
- **Mathematical modeling**: Simulating dynamic changes in cellular systems in response to pharmacologic stimuli.

Systems approaches are critical in diseases involving multifactorial dysregulation, such as cancer, neurodegenerative disorders, and autoimmune diseases. In such settings, targeting a single receptor may be insufficient; instead, multi-target or “polypharmacology” strategies are employed, aiming to modulate several nodes within a disease network.

Systems biology also enhances biomarker discovery by identifying molecular signatures of disease progression or therapeutic response. This is pivotal for precision medicine, where patients can be stratified into responders and non-responders based on their systems-level profiles.

Emerging tools such as single-cell RNA sequencing, CRISPR-based genetic screens, and machine learning-based network inference have dramatically expanded the capacity to analyze biological systems. These tools are enabling predictive models that forecast not only efficacy but also toxicity, drug-drug interactions, and resistance mechanisms [9].

1.4 Principles of Precision Medicine

Precision medicine or personalized medicine refers to the customization of healthcare, including pharmacologic treatment, to the individual characteristics of each patient. While traditional therapeutics are based on population averages, precision medicine aims to account for genetic, environmental, physiological, and lifestyle factors that influence drug response.

One of the cornerstones of precision pharmacology is pharmacogenomics, which studies how genetic polymorphisms affect drug metabolism, efficacy, and toxicity. Examples include:

- CYP2C19 polymorphisms affecting clopidogrel activation
- TPMT variants influencing thiopurine toxicity
- HLA-B*5701 allele predicting hypersensitivity to abacavir [10]

However, precision medicine extends beyond genomics. It encompasses:

- **Biomarker-driven therapy**: Using molecular diagnostics to guide drug choice (e.g., HER2 for trastuzumab, EGFR mutations for erlotinib).
- **Phenotypic profiling**: Utilizing metabolomics and proteomics to define disease subtypes or predict treatment responses.
- **Environmental and lifestyle factors**: Including diet, microbiome composition, and drug adherence patterns.

Technological advances have enabled the creation of multi-omic databases, which allow integration of diverse patient data into comprehensive risk models. These models inform decision-support tools, such as dosing algorithms and risk calculators, aiding clinicians in therapeutic planning.

Precision medicine also plays a vital role in clinical trials. Adaptive trial designs allow for dynamic modification of study arms based on interim analyses, enabling faster identification of effective therapies for genetically defined subgroups. Regulatory bodies like the FDA have increasingly supported companion diagnostics as part of drug approval, reinforcing the integration of precision tools in routine care [11].

The widespread implementation of precision therapeutics depends on infrastructure (e.g., bioinformatics capacity), clinician training, and patient access. Despite these challenges, it represents the future of pharmacology, moving from reactive to proactive, and from generalized to individualized care.

1.5 Pharmacological Modelling and Simulation

Pharmacological modeling and simulation are quantitative tools used to describe, predict, and optimize drug behavior within the body. These approaches are integral to both drug development and clinical decision-making, offering a bridge between preclinical findings and patient outcomes. There are several types of models used in system-based and precision pharmacology:

1. **Compartmental PK/PD models**
   - Simplify the body into compartments (e.g., central, peripheral)
   - Estimate key parameters: clearance, volume of distribution, absorption rate
2. **Physiologically Based Pharmacokinetic (PBPK) models**
   - Incorporate actual physiological variables: organ volumes, blood flow, enzyme levels
   - Useful for simulating drug behavior in special populations (e.g., pediatrics, renal impairment) [12]
3. **Mechanism-Based PK/PD models**
   - Incorporate receptor binding, signal transduction, and feedback mechanisms
   - Enable modeling of tolerance, delayed effects, and biomarker response
4. **Population PK (PopPK) models**
   - Analyze data from multiple individuals to identify sources of variability
   - Aid in precision dosing for heterogeneous populations
5. **Bayesian forecasting models**
   - Integrate prior knowledge and patient-specific data
   - Applied in therapeutic drug monitoring (TDM) of drugs like vancomycin or phenytoin

These models can simulate different dosing regimens, predict outcomes under varying physiological conditions, and guide clinical trial design. For example, PBPK models are increasingly used in regulatory submissions to support label expansions, drug-drug interaction (DDI) assessments, and pediatric extrapolations.

Moreover, virtual clinical trials based on in silico simulations are now used to reduce time and cost in early-phase drug development. These trials help identify optimal dosing, patient selection criteria, and safety risks before proceeding to human studies [13].

Model-informed precision dosing (MIPD) is gaining traction, particularly in oncology, infectious diseases, and transplantation medicine. It enables the integration of real-time patient data (e.g., drug levels, renal function) into dynamic dosing recommendations through clinical decision-support software.

As pharmacology continues to integrate systems and individualized approaches, modeling and simulation will be essential tools for navigating complexity, reducing uncertainty, and optimizing patient care.

1.6 Role of Omics in Pharmacology

The emergence of high-throughput "omics" technologies has revolutionized the field of pharmacology by enabling comprehensive analyses of biological systems. These include genomics, transcriptomics, proteomics, metabolomics, and epigenomics, each offering a distinct layer of insight into how drugs interact with the human body. Collectively, these technologies are integral to the development of precision therapeutics and have enhanced our understanding of drug efficacy, safety, and resistance mechanisms.

- **Genomics** investigates variations in DNA sequence, particularly single nucleotide polymorphisms (SNPs) that influence drug metabolism, such as those in CYP450 genes or drug transporters (e.g., SLCO1B1) [14]. Genomic data can identify responders and non-responders and guide the use of pharmacogenomic labels for drugs like warfarin and clopidogrel.
- **Transcriptomics** explores gene expression profiles. Differential expression of genes in diseases (e.g., cancer subtypes) can guide drug selection and stratify patients in clinical trials. mRNA expression of drug targets (e.g., HER2 in breast cancer) is now routinely used in precision oncology [15].
- **Proteomics** identifies protein abundance, modifications, and interactions. Since most drug targets are proteins, proteomic profiling provides functional insight beyond what is captured by genomic data. Mass spectrometry-based proteomics is used in biomarker discovery, such as predicting response to kinase inhibitors.
- **Metabolomics** offers a snapshot of biochemical activity and metabolic shifts due to drug action or disease. It is especially valuable for identifying drug-induced toxicities (e.g., nephrotoxicity signatures) and monitoring treatment response in real time [16].
- **Epigenomics** studies DNA methylation, histone modification, and non-coding RNAs that regulate gene expression without altering the DNA sequence. Epigenetic alterations are increasingly targeted in cancer therapy, and their modulation may influence drug sensitivity.

The integration of omics data referred to as multi-omics enables a systems-level view of disease mechanisms and therapeutic responses. Platforms combining omics datasets with AI tools are now used for drug repurposing, target identification, and toxicity prediction.

Pharmacology is also benefitting from pharmaco-omics, a discipline that combines pharmacology with multiple omics layers to understand inter-individual variability. These data-rich approaches are the cornerstone of network-based pharmacology and personalized medicine, especially in oncology, neurology, and rare diseases [17].

1.7 Challenges in Systemic Integration

Despite the promise of system-based pharmacology and precision therapeutics, several barriers impede their widespread clinical implementation. These challenges are multifactorial and span scientific, technological, regulatory, and ethical domains.

1. **Biological Complexity and Network Redundancy**
   Biological systems are inherently redundant and adaptable. Targeting a single node often results in compensatory pathway activation, which can undermine drug efficacy or introduce new adverse effects. In oncology, inhibition of one kinase may lead to activation of alternate survival pathways [18].
2. **Data Heterogeneity and Standardization**
   Integrating multi-omics, clinical, and environmental data is technically challenging. Variability in sample quality, measurement platforms, and data preprocessing affects reproducibility. Standardized pipelines and reference databases are still evolving.
3. **Inter-Individual Variability**
   Even with precise data, predicting drug response is difficult due to the interplay of genetic, environmental, and behavioral factors. For example, two patients with identical genotypes may respond differently due to microbiome differences or drug interactions.
4. **Computational Limitations**
   Simulating biological systems requires advanced algorithms and large computational resources. While AI and machine learning have accelerated progress, model validation and interpretability remain concerns in clinical translation.
5. **Cost and Infrastructure Barriers**
   Omics technologies, clinical decision-support tools, and modeling platforms are resource-intensive. Limited access in low-resource settings can widen health disparities.
6. **Regulatory and Legal Uncertainties**
   Frameworks for regulating AI-based decision tools, genetic data usage, and dynamic dosing software are still under development. Ensuring patient safety while encouraging innovation is a delicate balance [19].
7. **Clinician Training and Adoption**
   Many healthcare providers lack training in interpreting pharmacogenomic or model-informed dosing outputs. Integrating these tools into workflows without increasing complexity is essential for uptake.

Despite these hurdles, incremental advances in technology, policy, and education are steadily improving the feasibility of systemic integration. Multidisciplinary collaboration across pharmacology, bioinformatics, clinical medicine, and regulatory science is key to overcoming these limitations.

1.8 Regulatory Framework for Precision Therapeutics

As the field of precision pharmacology evolves, regulatory agencies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others have begun adapting their frameworks to accommodate new modalities, diagnostics, and data-driven decision tools.

1. Companion Diagnostics and Drug Approval

The FDA defines companion diagnostics (CDx) as tests essential for the safe and effective use of a corresponding drug. Approval of targeted therapies (e.g., trastuzumab, vemurafenib) now requires co-approval of companion tests to stratify patients [20].

2. Model-Informed Drug Development (MIDD)
Regulatory bodies support the use of PBPK models, exposure-response modeling, and Bayesian forecasting to justify dose selection, drug interactions, and labeling decisions. MIDD is particularly useful in pediatrics and rare diseases, where trial data may be limited.

3. Real-World Evidence (RWE)
Regulators are increasingly accepting real-world data from electronic health records (EHRs), wearable devices, and registries to support post-market surveillance and label updates. RWE is crucial for long-term safety monitoring and adaptive approval pathways.

4. Pharmacogenomic Labeling
Many drugs now carry genomic biomarker information in their labels. Regulatory efforts continue to standardize test interpretation, allele nomenclature, and clinical relevance (e.g., CPIC, PharmGKB harmonization).

5. AI and Clinical Decision-Support Tools
Regulatory guidance for AI-based tools remains nascent. The FDA's Software as a Medical Device (SaMD) framework offers initial direction, but issues around algorithm transparency, data bias, and re-validation of learning systems remain under discussion.

6. Global Harmonization and Guidelines
The **International Council for Harmonisation (ICH)** has expanded guidance documents (e.g., E6-R3, E11A) to include risk-based approaches, model-based dosing, and age-specific considerations in drug development.

While regulatory agencies are promoting innovation, they emphasize robust evidence, reproducibility, and patient safety. Ongoing dialogue between industry, academia, and regulatory stakeholders is crucial to ensure that new precision therapeutics reach patients in a timely and safe manner.

1.9 Future Directions

The future of pharmacology lies at the intersection of systems biology, precision medicine, and digital innovation. As emerging technologies converge, a new era of data-driven, patient-specific therapeutics is taking shape one that promises not only enhanced efficacy but also improved safety and accessibility.

1. Artificial Intelligence (AI) in Drug Discovery and Development
AI and machine learning are being used to identify novel drug targets, predict off-target effects, simulate pharmacokinetic profiles, and optimize compound design. Algorithms trained on omics datasets and clinical outcomes can now propose repurposed drugs and generate hypothesis-free insights [21].

2. Digital Twins in Pharmacology
Digital twins virtual models of individual patients integrate genetic, physiological, and real-time health data to simulate how a person will respond to a given drug or dosage. This approach holds promise in oncology, transplantation, and rare diseases [22].

3. Closed-Loop Drug Delivery Systems
Smart implants and wearable biosensors are enabling real-time drug administration based on physiologic feedback. Closed-loop insulin pumps for diabetes and sensor-based chemotherapy dosing are early examples.

4. Advanced Therapeutics: RNA, Gene, and Cell-Based Drugs

siRNA therapies (e.g., patisiran), mRNA vaccines (e.g., COVID-19 vaccines), and CRISPR gene-editing treatments are redefining what constitutes a "drug." These therapeutics act at the genetic or transcriptional level and are often personalized to the patient's genomic profile.

5. Polypharmacology and Multi-Target Approaches

Drugs targeting multiple nodes within a disease network may offer superior efficacy and resistance mitigation. Rational polytherapy, aided by systems modeling, is gaining traction in fields like neurodegeneration and oncology.

6. Microbiome-Informed Pharmacology

Growing evidence shows that the gut microbiota affects drug metabolism, immune modulation, and therapeutic outcomes. Future drug development may consider microbiome composition as a modifiable co-factor [23].

7. Democratizing Precision Medicine

Advances in low-cost genomic sequencing, open-access AI tools, and mobile health platforms are expected to make precision therapeutics more accessible globally. Community genomics and decentralized trials are promising trends.

8. Regulatory Innovation and Dynamic Approvals

Adaptive licensing, real-world data integration, and cloud-based pharmacovigilance systems will likely become regulatory norms, supporting rapid innovation while maintaining safety standards.

Ultimately, the integration of bioinformatics, engineering, clinical pharmacology, and ethics will define the next generation of drug development and delivery. The pharmacologist of the future must be not only a scientist but also a systems thinker, capable of translating complex data into meaningful clinical action.

1.10 SUMMARY AND CONCLUSION

This chapter introduced the foundational shift from reductionist, organ-specific pharmacology to a more holistic, system-based model that integrates biological complexity and individual variability. Key principles of pharmacokinetics, pharmacodynamics, receptor theory, and signal transduction were revisited within the context of systemic interconnectivity and real-time feedback mechanisms.

We explored how systems biology has enabled deeper understanding of drug responses across multiple biological levels, and how omics technologies provide high-resolution snapshots of the patient's internal landscape. These insights have converged in the field of precision therapeutics, where treatment is tailored based on genomics, phenotypes, and lifestyle factors.

To operationalize such complexity, modeling and simulation tools like PBPK and PopPK models are now standard in pharmacologic research and clinical application. Despite scientific and operational challenges, precision pharmacology is progressing rapidly, aided by regulatory flexibility and technological advances.

Looking forward, innovations such as AI-driven drug discovery, digital health platforms, smart delivery devices, and cell-based therapeutics will continue to reshape the therapeutic landscape. System-based and precision pharmacology are not just theoretical ideals they are the cornerstones of 21st-century healthcare.

Pharmacologists, clinicians, and researchers must work collaboratively to translate these tools into better outcomes for patients. In doing so, they will not only improve efficacy and safety but also realize the vision of truly individualized medicine.

REFERENCES

1. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-141.
2. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: Concepts and applications. CRC Press; 2016.
3. Holford N, Ma SC, Ploeger BA. Clinical trial simulation: A review. Clin Pharmacol Ther. 2010;88(2):166–182.
4. Kenakin T. A Pharmacology Primer: Theory, Applications, and Methods. Academic Press; 2018.
5. Hilfiker-Kleiner D, Hilfiker A, Drexler H. Many good reasons to have the blues: The NO/cGMP pathway in cardiac remodeling. J Am Coll Cardiol. 2005;46(5):813–815.
6. Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev. 2001;81(1):299–343.
7. Luttrell LM, Gesty-Palmer D. Beyond desensitization: Physiological relevance of arrestin-dependent signaling. Pharmacol Rev. 2010;62(2):305–330.
8. Stein EA, Raal FJ. Lipid-lowering strategies: Focus on niacin. Curr Atheroscler Rep. 2010;12(1): 64–71.
9. Ekins S, Nikolsky Y, Bugrim A, Kirillov E, Nikolskaya T. Pathway mapping tools for analysis of high content data. Methods Mol Biol. 2007;356:319–350.
10. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350.
11. Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015;520(7549):609–611.
12. Jones HM, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol. 2013;2(8):e63.
13. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions. Clin Pharmacol Ther. 2005;78(1):31–38.
14. Caudle KE, Rettie AE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2017;102(3):397–404.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11): 783–792.
16. Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature. 2008;455(7216):1054–1056.
17. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361–369.
18. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679–692.
19. US FDA. Artificial Intelligence and Machine Learning in Software as a Medical Device. 2021.
20. Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.
21. Corral-Acero J, Margara F, Marciniak M, et al. The ‘Digital Twin’ to enable the vision of precision cardiology. Eur Heart J. 2020;41(48):4556–4564.
22. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570(7762):462–467.

1 

Santhosh Illendula
Associate Professor,
Department of Pharmaceutical Analysis,
Vijaya College of Pharmacy, Munaganoor,
Hyderabad, Telangana, India.

2 

Prof. Thirumurugan R
Principal, Niveditha College of Pharmacy,
Chintamani, Chickballapur District,
Karnataka, India.